Synergistic drug combinations prediction by integrating pharmacological data

There is compelling evidence that synergistic drug combinations have become promising strategies for combating complex diseases, and they have evident predominance comparing to traditional one drug - one disease approaches. In this paper, we develop a computational method, namely SyFFM, that takes pharmacological data into consideration and applies field-aware factorization machines to analyze and predict potential synergistic drug combinations. Firstly, features of drug pairs are constructed based on associations between drugs and target, and enzymes, and indication areas. Then, the synergistic scores of drug combinations are obtained by implementing field-aware factorization machines on latent vector space of these features. Finally, synergistic combinations can be predicted by introducing a threshold. We applied SyFFM to predict pairwise synergistic combinations and three-drug synergistic combinations, and the performance is good in terms of cross-validation. Besides, more than 90% combinations of the top ranked predictions are proved by literature and the analysis of parameters in model shows that our method can help to investigate and explain synergistic mechanisms underlying combinatorial therapy.

[1]  Xing Chen,et al.  NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..

[2]  Steven T. Nakajima,et al.  Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive , 2013, Obstetrics and gynecology.

[3]  Abid Ahmad Sofi,et al.  Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[4]  Xin Chen,et al.  DCDB: Drug combination database , 2010, Bioinform..

[5]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[6]  Edmund Luo,et al.  Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. , 2009, Current medical research and opinion.

[7]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[8]  R. Frederich,et al.  Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin , 2013, International journal of clinical practice.

[9]  Donald A. Smith,et al.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. , 2006, American heart journal.

[10]  A. Genazzani,et al.  Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. , 2001, American journal of obstetrics and gynecology.

[11]  Melanie J. Davies,et al.  Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study , 2009, Current medical research and opinion.

[12]  Sándor Pongor,et al.  Predicting effective drug combinations via network propagation , 2013, 2013 IEEE Biomedical Circuits and Systems Conference (BioCAS).

[13]  Yoshihiro Yamanishi,et al.  Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles , 2015, J. Chem. Inf. Model..

[14]  Chih-Jen Lin,et al.  Field-aware Factorization Machines for CTR Prediction , 2016, RecSys.

[15]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[16]  Wei Li,et al.  Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles , 2017, Artif. Intell. Medicine.

[17]  Yi Xiong,et al.  Prediction of Effective Drug Combinations by an Improved Naïve Bayesian Algorithm , 2018, International journal of molecular sciences.

[18]  Susumu Goto,et al.  LIGAND: database of chemical compounds and reactions in biological pathways , 2002, Nucleic Acids Res..

[19]  Michael Noonan,et al.  Efficacy and Safety of Budesonide and Formoterol in One Pressurised Metered-Dose Inhaler in Adults and Adolescents with Moderate to Severe Asthma , 2012, Drugs.

[20]  Xing Chen,et al.  ASDCD: Antifungal Synergistic Drug Combination Database , 2014, PloS one.

[21]  Qiuhong Wang,et al.  Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome , 2016, Scientific Reports.

[22]  M. Dickson,et al.  The cost of new drug discovery and development. , 2004, Discovery medicine.

[23]  J. Gustafsson,et al.  Progesterone receptor-estrogen receptor crosstalk: a novel insight , 2015, Trends in Endocrinology & Metabolism.

[24]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[25]  L. Mansfield,et al.  Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. , 2013, Respiratory medicine.

[26]  Lei Chen,et al.  Prediction of Effective Drug Combinations by Chemical Interaction, Protein Interaction and Target Enrichment of KEGG Pathways , 2013, BioMed research international.

[27]  R. DeFronzo,et al.  Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  Roland Chen,et al.  Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes , 2011, Postgraduate medicine.

[29]  Ting-I Lee,et al.  The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. , 2013, International journal of cardiology.

[30]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[31]  David R Owens,et al.  Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial , 2012, The Lancet.

[32]  Kirsten McAulay,et al.  Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial , 2013, Current medical research and opinion.

[33]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[34]  R. Pratley,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study , 2009, Current medical research and opinion.

[35]  Xuelin He,et al.  Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. , 2014, JAMA internal medicine.

[36]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[37]  Yi Xiong,et al.  A Hadoop-Based Method to Predict Potential Effective Drug Combination , 2014, BioMed research international.

[38]  Di Chen,et al.  Systematic synergy modeling: understanding drug synergy from a systems biology perspective , 2015, BMC Systems Biology.

[39]  Xiu-Jie Zhou,et al.  [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. , 2013, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[40]  Lai Wei,et al.  Analysis and prediction of drug–drug interaction by minimum redundancy maximum relevance and incremental feature selection , 2017, Journal of biomolecular structure & dynamics.

[41]  Chih-Jen Lin,et al.  Training and Testing Low-degree Polynomial Data Mappings via Linear SVM , 2010, J. Mach. Learn. Res..

[42]  E. Papanikolaou,et al.  GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. , 2013, Human reproduction.

[43]  Stefan Peterson,et al.  Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. , 2010, Respiratory medicine.

[44]  B. Schwab,et al.  Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. , 2011, Respiratory medicine.

[45]  Roland Chen,et al.  Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus , 2011, Diabetes & vascular disease research.

[46]  P. Amouyel,et al.  Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries. , 1997, Heart.